Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 24, 2023 - Issue 12
Submit an article Journal homepage
503
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy

Efrat Luttwaka Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0212-2135View further author information
ORCID Icon,
Mitchell R. Smithb The Follicular Lymphoma Foundation, Washington, USAORCID Iconhttps://orcid.org/0000-0003-1428-8765View further author information
ORCID Icon &
Andrew D. Zelenetza Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USAORCID Iconhttps://orcid.org/0000-0003-1403-6883View further author information
ORCID Icon
Pages 1331-1334 | Received 29 Mar 2023, Accepted 06 Jun 2023, Published online: 12 Jun 2023

References

  • Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194–204. doi:10.1016/j.tibs.2005.02.008
  • Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317–330. doi:10.1038/nri1056.
  • von Keudell G, Moskowitz AJ. The role of PI3K inhibition in lymphoid malignancies. Curr Hematol Malignancy Rep. 2019;14(5):405–413. doi:10.1007/s11899-019-00540-w.
  • [FDA Briefing Document]; Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/157762/download.
  • Richardson NC, Kasamon Y, Pazdur R, et al. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23(5):563–566. doi:10.1016/S1470-2045(22)00200-5
  • Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa1314583
  • Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905. doi:10.1200/JCO.2017.75.4648
  • Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–922. doi:10.1200/JCO.18.00915
  • Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε Inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39(15):1609–1618. doi:10.1200/JCO.20.03433
  • Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311. doi:10.1016/S1470-2045(16)30671-4
  • Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi:10.1056/NEJMoa1315226
  • Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114–e126. doi:10.1016/S2352-3026(17)30019-4
  • Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678–689. doi:10.1016/S1470-2045(21)00145-5
  • Gribben JG, Jurczak W, Jacobs RW, et al. Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+chl) in patients with treatment naïve (TN) and Relapsed/Refractory (R/R) chronic lymphocytic leukemia (CLL): results from the phase 3 unity-CLL study. Blood. 2020;136(Supplement 1):37–39. doi:10.1182/blood-2020-134783
  • Winkler DG, Faia K, DiNitto J, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–1374. doi:10.1016/j.chembiol.2013.09.017
  • Moreno O, Butler T, Zann V, et al. Safety, pharmacokinetics, and pharmacodynamics of ME-401, an oral, potent, and selective inhibitor of phosphatidylinositol 3-kinase P110δ, following single ascending dose administration to healthy volunteers. Clin Ther. 2018;40(11):1855–1867. doi:10.1016/j.clinthera.2018.09.006
  • Pagel JM, Soumerai JD, Reddy N, et al. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022;23(8):1021–1030. doi:10.1016/S1470-2045(22)00333-3.
  • Zelenetz AD, Jurczak W, Ribrag V, et al. Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) Follicular Lymphoma (FL): final results of the tidal phase 2 study. Blood. 2022;140(Supplement 1):3595–3597. doi:10.1182/blood-2022-165409.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.